ritlecitinib
Selected indexed studies
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. (Lancet, 2023) [PMID:37062298]
- Ritlecitinib: First Approval. (Drugs, 2023) [PMID:37556041]
- Ritlecitinib. (, 2012) [PMID:38630973]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. (2025) pubmed
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. (2023) pubmed
- Ritlecitinib: First Approval. (2023) pubmed
- Ritlecitinib. (2012) pubmed
- Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. (2023) pubmed
- Ritlecitinib. (2006) pubmed
- Ritlecitinib. (2006) pubmed
- Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. (2025) pubmed
- Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo. (2024) pubmed
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. (2024) pubmed